Compare SFHG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFHG | TSHA |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 1.7B |
| IPO Year | 2022 | 2020 |
| Metric | SFHG | TSHA |
|---|---|---|
| Price | $2.04 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 3.6K | ★ 3.5M |
| Earning Date | 09-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,023.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $0.32 | $3.46 |
| 52 Week High | $3.17 | $7.30 |
| Indicator | SFHG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 54.62 |
| Support Level | $1.95 | $4.33 |
| Resistance Level | $2.17 | $4.59 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 84.20 | 97.96 |
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.